Concepts (47)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 2 | 2023 | 3869 | 0.650 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 264 | 0.560 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 1763 | 0.550 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 406 | 0.520 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 442 | 0.510 |
Why?
|
| Patient Safety | 1 | 2019 | 649 | 0.460 |
Why?
|
| Genetic Therapy | 1 | 2019 | 1616 | 0.400 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1870 | 0.380 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 121 | 0.200 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 289 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 335 | 0.190 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 246 | 0.180 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 362 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 709 | 0.170 |
Why?
|
| Neoplasms | 2 | 2022 | 15193 | 0.170 |
Why?
|
| Catheter-Related Infections | 1 | 2022 | 270 | 0.170 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 482 | 0.170 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 245 | 0.150 |
Why?
|
| Cross Infection | 1 | 2022 | 544 | 0.150 |
Why?
|
| Sepsis | 1 | 2022 | 652 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 694 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 6550 | 0.130 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 2638 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 1146 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 1399 | 0.100 |
Why?
|
| Child | 5 | 2023 | 29154 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 2796 | 0.090 |
Why?
|
| Humans | 8 | 2023 | 261506 | 0.080 |
Why?
|
| Genomics | 1 | 2019 | 2738 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 14889 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2019 | 6869 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2023 | 37905 | 0.060 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 180 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2022 | 88 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 140 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 764 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2019 | 32848 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 1581 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 915 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 3001 | 0.030 |
Why?
|
| Adult | 1 | 2022 | 77950 | 0.030 |
Why?
|
| Recurrence | 1 | 2023 | 4758 | 0.030 |
Why?
|
| Male | 1 | 2019 | 123000 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 12873 | 0.020 |
Why?
|
| Female | 1 | 2019 | 141928 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13310 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2023 | 16273 | 0.020 |
Why?
|